Glaukos (NYSE:GKOS) Director Gilbert Kliman Sells 5,000 Shares of Stock

Posted by Stanley Muller on May 14th, 2026

Glaukos Corporation (NYSE:GKOS – Get Free Report) Director Gilbert Kliman sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $135.00, for a total value of $675,000.00. Following the sale, the director directly owned 35,528 shares of the company’s stock, valued at $4,796,280. The trade was a 12.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Glaukos Stock Up 0.6%

Shares of GKOS stock opened at $137.19 on Thursday. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $146.75. The firm has a market cap of $8.06 billion, a PE ratio of -41.83 and a beta of 0.94. The stock has a 50 day moving average of $116.05 and a 200-day moving average of $110.69. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The company had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. During the same period in the previous year, the company earned ($0.22) earnings per share. The company’s quarterly revenue was up 41.2% compared to the same quarter last year. On average, equities analysts predict that Glaukos Corporation will post -0.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on GKOS. BTIG Research upped their price target on Glaukos from $131.00 to $141.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Stifel Nicolaus set a $170.00 price target on Glaukos in a report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. Piper Sandler reiterated an “overweight” rating and set a $165.00 price target on shares of Glaukos in a report on Wednesday, January 14th. Finally, Wells Fargo & Company upped their price target on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and a consensus price target of $144.42.

Get Our Latest Analysis on GKOS

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GKOS. Janus Henderson Group PLC raised its stake in shares of Glaukos by 183.4% in the fourth quarter. Janus Henderson Group PLC now owns 3,018,787 shares of the medical instruments supplier’s stock valued at $340,855,000 after purchasing an additional 1,953,578 shares in the last quarter. Primecap Management Co. CA raised its stake in shares of Glaukos by 49.8% in the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock valued at $381,289,000 after purchasing an additional 1,123,140 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Glaukos by 209.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock valued at $152,476,000 after purchasing an additional 913,458 shares in the last quarter. Millennium Management LLC raised its stake in shares of Glaukos by 75.3% in the fourth quarter. Millennium Management LLC now owns 1,609,699 shares of the medical instruments supplier’s stock valued at $181,751,000 after purchasing an additional 691,289 shares in the last quarter. Finally, UBS Group AG raised its stake in shares of Glaukos by 316.0% in the fourth quarter. UBS Group AG now owns 873,942 shares of the medical instruments supplier’s stock valued at $98,677,000 after purchasing an additional 663,849 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Company Profile

(Get Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.